ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Sep 2023
Last Updated on 01 Sep 2023
A- A+
Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing dexamethasone 0.7 mg intravitreal implant on the MOH List of Subsidised Drugs for treating diabetic macular oedema, macular oedema following retinal vein occlusion and non-infectious uveitis affecting the posterior segment of the eye. The decision was based on the unfavourable clinical and cost-effectiveness of intravitreal dexamethasone implant compared with current treatment options.


Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis (Published 1 Sep 23) PES Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis (Published 1 Sep 23)